Exploring Robotic radiotherapy Market Trends: Companies Leading Growth

Comments · 66 Views

Leading the Robotic Radiotherapy market are key players such as Accuray, Varian Medical Systems, and Elekta AB. Their innovations in precision and efficiency are revolutionizing cancer treatment, offering hope and improved outcomes for patients worldwide.

The global Robotic Radiotherapy Market is projected to reach USD 1.9 billion by 2028 from USD 1.1 billion in 2023, growing at a CAGR of 11.9% during the forecast period. The growing use of the robotic radiotherapy market for cancer treatment is propelled by increasing adoption driven by technological advancements and a rising prevalence of cancer. Growing demand for non-invasive treatments further fuels this growth. Additionally, increased healthcare expenditure in developing countries, coupled with government and private investments, bolster the adoption of radiotherapy. However, challenges such as inadequate healthcare infrastructure, high costs associated with robotic radiotherapy, technological complexity, and a shortage of skilled radiologists are anticipated to impede market growth in the forecast period.

The robotic radiotherapy business is very competitive, with both established companies and newcomers competing for the same market share. As of 2022, the key players operating in the global robotic radiotherapy market are Siemens Healthineers AG (Germany), Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuray Incorporated (US), IBA Worldwide (Belgium), and ViewRay, Inc. (US), among others.

Download the PDF Brochure at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122256158utm_source=Ganeshutm_medium=P

Siemens Healthineers AG (Germany)

In 2022, Siemens Healthineers AG became the leading player in the robotic radiotherapy market after the successful acquisition of Varian Medical Systems, Inc. (US) in April 2021. To expand its geographical footprint, the company emphasizes both organic and inorganic growth strategies. A strong focus on the expansion of RD activities in the areas of artificial intelligence (AI), robotics, and sensing technology, has enabled the company to introduce novel products. Varian medical systems, Inc., under Siemens Healthineers, has introduced and received regulatory approvals for the ProBeam proton therapy system, ProBeam 360 with multi-room configuration, and Halcyon system.

Siemens Healthineers AG, through Varian Medical Systems, Inc., has also entered into several agreements, partnerships, collaborations, and contracts during the last three years to enhance its market presence. These deals have helped the company strengthen its position in the global robotic radiotherapy market.

Elekta (Sweden)

In 2022, Elekta will be another leading player in the robotic radiotherapy market, including products and services. The company has a strong brand presence in North America, Europe, and Asia (especially in China, India, and East Asia. Elekta has established its direct presence in the Philippines and Indonesia to gain a larger market share in the Asian market. The company also has an established custom services support setup, which helps it strengthen customer relationships and its presence in the robotic radiotherapy market.

Direct Purchase at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=122256158utm_source=Ganeshutm_medium=P

Elekta provides its radiotherapy products to more than 6,000 hospitals and cancer research institutes worldwide, and the company has installed a base of 7,150 radiotherapy devices, of which about 5,250 were LINAC systems by the end of 2022. The demand for Elekta’s products is high among end users owing to their high quality and strong brand image.

Comments